Sharon Fekrat discusses the complexities of antithrombotic use in wet AMD, highlighting the need for individualized treatment and future guideline development. Sharon Fekrat, MD, FACS, FASRS, ...

Although my practice is primarily an anterior segment practice, the care of patients with age-related macular degeneration (AMD) is something I have always followed closely. AMD is the leading cause ...

Two FDA-approved geographic atrophy treatments show significant patient dropout, with 45% discontinuation by 18 months, driven by baseline vision, CNV, and lack of immediate visual improvement. In a ...

This phase 2b study (ASPIRE) is currently underway. UNITY believes that its lead candidate, UBX1325 (foselutoclax), with its unique mechanism of action, has the potential to improve long-term visual ...

Aviceda Therapeutics has completed enrollment of the phase 2b trial of the SIGLEC Study. The study will assess the safety and efficacy of AVD-104, the company’s formulation designed to treat ...

The value of attending industry meetings at the beginning of a career in ophthalmology. Attending the American Academy of Ophthalmology (AAO) Annual Meeting for the first time can feel overwhelming.

This follows successful Phase 1 results, which demonstrated a favorable safety profile for BI 771716 across both single and multiple intravitreal doses. CDR-Life under its collaboration and licensing ...

The biosimilar now known by the brand name OPUVIZ was previously known as the biosimilar candidate SB15. The European Commission (EC) has approved OPUVIZ 40 mg/mL solution for injection in a vial.

Drs Nathan Steinle, Adrienne Scott, Carl Regillo, and Prethy Rao share their approaches to dosing recommendations for faricimab in the treatment of neovascular AMD.

The results of a new retrospective cohort study suggest that use of curcuma-based nutritional supplements (CBNS) may be associated with the reduced risk of developing age-related macular degeneration ...

Firas Rahhal, MD, discusses Outlook Therapeutics’ Phase 3 pivotal NORSE TWO trial for ONS-5010. Firas Rahhal, MD, discusses the results of Outlook Therapeutics’ pivotal NORSE TWO trial for ONS-5010.

Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might ...